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Abstract
Background: The goal of this research was to compare the demographics, clinical characteristics and treatment
patterns for newly diagnosed multiple sclerosis (MS) patients in a commercial managed care population who
received disease-modifying drug (DMD) therapy versus those not receiving DMD therapy.
Methods: A retrospective cohort study using US administrative healthcare claims identified individuals newly
diagnosed with MS (no prior MS diagnosis 12 months prior using ICD-9-CM 340) and ≥ 18 years old during 2001-
2007 to characterize them based on demographics, clinical characteristics, and pharmacologic therapy for one year
prior to and a minimum of one year post-index. The index date was the first MS diagnosis occurring in the study
period. Follow-up of subjects was done by ICD-9-CM code identification and not by actual chart review.
Multivariate analyses were conducted to adjust for confounding variables.
Results: Patients were followed for an average of 35.7 ± 17.5 months after their index diagnosis. Forty-three
percent (n = 4,462) of incident patients received treatment with at least one of the DMDs during the post-index
period. Treated patients were primarily in the younger age categories of 18-44 years of age, with DMD therapy
initiated an average of 5.3 ± 9.1 months after the index diagnosis. Once treatment was initiated, 27.7%
discontinued DMD therapy after an average of 17.6 ± 14.6 months, and 16.5% had treatment gaps in excess of 60
days.
Conclusions: Nearly 60% of newly-diagnosed MS patients in this commercial managed care population remained
untreated while over a quarter of treated patients stopped therapy and one-sixth experienced treatment gaps
despite the risk of disease progression or a return of pre-treatment disease activity.
Background
Multiple sclerosis (MS) is a complex, recurrent, and
progressive autoimmune disease of the central nervous
system affecting an estimated 250,000 to 400,000 people
in the US. Primarily diagnosed in young adults at a
mean age of 29 years, it follows four recognized disease
courses: relapsing/remitting MS (RRMS), secondary pro-
gressive MS (SPMS), primary progressive MS (PPMS),
and progressive relapsing MS (PRMS) [1-4]. Approxi-
mately 20% of patients have a mild form of the disease,
yet MS can also render a person unable to write, speak,
or walk, with up to 60% of patients losing ambulatory
capability within 20 years after onset [1,2,5]. Since most
people with MS have a fairly normal life expectancy,
this chronic disease evokes very significant social, medi-
cal and economic impacts.
MS is neither easy nor quick to diagnose, especially in
its early stages, compounded by the often transient nat-
ure of attacks, variability in symptoms, other diseases
producing similar symptoms, and the lack of a specific
unequivocal diagnostic test [1-4,6,7]. Clinical diagnosis
often requires several strategies to determine if a person
meets the established criteria (e.g., The Revised McDo-
nald Criteria), including a detailed medical history, neu-
rologic exams, magnetic resonance imaging (MRI),
evoked potentials (EP) and spinal fluid analysis [7-9].
Symptoms may vary in frequency, severity and form,
and so patients diagnosed with clinically definite MS
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often drawn out over months or years [10-17].
There is presently no known cure for MS. Current
treatments for MS are aimed at returning function after
an attack, preventing new attacks, managing symptoms
and preventing or postponing long-term disability [18].
Acute symptomatic attacks are most often treated with
high dose glucocorticoids, however there does not
appear to be any long-term functional benefit from their
use [18,19]. Several disease-modifying drugs (DMDs)
have been found to reduce the relapse rate, reduce
lesion development, positively affect MRI metrics and
disease progression, and improve the quality of life for
many MS patients [3,18,20-23]. Six parenterally adminis-
tered DMDs are currently approved for immunomodula-
tory and immunosuppressive treatment of relapsing and
secondary-progressive MS (in alphabetical order): glatir-
amer acetate, interferon beta 1a–intramuscular, inter-
feron beta 1a–subcutaneous, interferon beta 1b,
mitoxantrone, and natalizumab [21]. DMD treatment
can be sustained indefinitely, as long as there is evidence
of benefit, particularly since cessation of therapy may
result in returning to pre-treatment disease activity
[21,24-29].
The decision to begin or continue MS therapy is com-
plex and controversial [5]. The National Multiple Sclero-
sis Disease Management Consensus Statement [21]
recommends initiating interferon beta or glatiramer
DMD therapy as soon as possible following definite diag-
nosis of active, relapsing MS, and also to consider DMD
therapy for selected high risk patients with a first attack.
A l t h o u g ht h eD M D sh a v ep o s i t i v e l ya f f e c t e dt h et r e a t -
ment and course of RRMS, numerous factors including
their parenteral route of administration, injection anxiety,
side effects, unobservable improvement, adjunctive ther-
apy, and treatment fatigue can affect the initiation and
continuation of DMD therapies [5,17,23,25-29].
The objective of the current research was to under-
stand the differences in demographics, clinical charac-
teristics and treatment patterns between newly
diagnosed MS patients in a commercial managed care
population who received DMD therapy versus those not
receiving DMD therapy.
Methods
Study design
This retrospective cohort study used administrative
healthcare claims from a database of US-based employ-
ers and health insurers to identify individuals newly
diagnosed with MS during 2001-2007 and to construct a
detailed claims history for each individual. Patients were
characterized based on their demographics and baseline
clinical indicators (diagnoses, comorbidities, concomi-
tant medications) during the year prior to the index
diagnosis, and then followed for at least one year to
assess healthcare resource utilization, medical expendi-
tures, treatments, and adherence to therapy.
Data source
Data came from two Thomson Reuters MarketScan
®
research databases: the Commercial Claims and Encoun-
ters (Commercial) database and the Medicare Supple-
mental and Coordination of Benefits (Medicare)
database, from January 1, 2000, through December 31,
2007. The Commercial database contained the inpatient,
outpatient, and outpatient prescription drug experience
of 44.5 million employees and their dependents under a
variety of insurance coverage types. The Medicare data-
base contained the healthcare experience of 4.5 million
individuals with Medicare supplemental insurance paid
for by employers, including both the Medicare-covered
portion of payment and the employer-paid portion. All
database records were de-identified and fully compliant
with US patient confidentiality requirements (HIPAA).
Sample selection and study period
Selected patients were a minimum of 18 years old with a
diagnosis of MS (ICD-9-CM code 340) between January
1, 2001, and January 1, 2007 (patient selection period).
A minimum of one inpatient or emergency department
claim, or more than one outpatient claim at least 30
days apart with ICD-9-CM 340 (excluding diagnostic
laboratory and diagnostic radiology claims; also referred
to herein as “non-diagnostic” claims) was required. The
index diagnosis date was assigned to the earlier of the
first medical claim with an MS diagnosis or the date of
the first medical or pharmacy claim for one of the
DMDs during the patient selection period. Patients were
required to have at least 12 months of continuous
health plan eligibility with both medical and pharmacy
benefits both before and following their index diagnosis
date. To identify patients as “incident” or newly diag-
nosed, they were required to have no claims with a diag-
nosis of MS or any DMD therapy during the 12-months
prior to their index diagnosis date. The study used
administrative claims data in the absence of the patient
medical charts, therefore relying on the diagnoses coded
by the provider and the patient history found only
within the healthcare claims. Patients were followed for
a minimum of 12 months from their index date and
then for as long as the data were available or until the
end of calendar year 2007. Follow-up of subjects was
done by ICD-9-CM code identification and not by
actual chart review.
Outcome measures
Diagnoses, medical procedures and pharmacologic ther-
apy were derived from medical and pharmacy claims
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index and post-index periods. MS diagnoses and comor-
bidities were determined from medical claims (excluding
diagnostic laboratory and radiology claims). A diagnosis
code entered in any position for the claim was used.
Pharmacologic therapy was identified from pharmacy
claims and from HCPCS codes in medical claims. Medi-
cal procedures or diagnostic evaluations were identified
from CPT-4 codes or ICD-9-CM procedure codes in
medical claims. Drugs for treating MS were analyzed
individually and by drug class.
Demographic data included age, gender, insurance
plan type (comprehensive, EPO, HMO, POS, POS with
c a p i t a t i o n ,P P O ,a n do t h e r ) ,g e o g r a p h i cr e g i o na n d
length of follow-up. Clinical data included monitoring
for selected comorbidities in medical claims, computa-
tion of the Deyo-Charlson comorbidity index (measured
pre-index), use of DMD therapy, other pharmacological
treatments for MS symptoms, and medical procedures
and diagnostic tests associated with MS.
Treatment pattern analyses included time to DMD
therapy initiation (for patients treated), persistence on
therapy and discontinuation patterns. The length of con-
tinuous treatment with the index DMD was determined
by considering the days supplied listed on the index
drug claim(s), as well as the fill date and days supplied
for subsequent claims of the same medication, including
medical claims showing DMD administration. The
length of index DMD therapy was defined as “continu-
ous” by calculating days across consecutive prescription
or medical claims of the index drug with no gaps of
more than 30 days. A gap between consecutive prescrip-
tions of the index drug is typically allowed because
patients may not fill prescriptions the exact day they are
due for a refill. The number of patients with gaps in
therapy of 31-60 days, 61-90 days, 91-120 days and
>120 days were also tracked. Gaps for patients receiving
natalizumab and mitoxantrone were adjusted to accom-
modate for their longer dosing intervals, assuming 4
weeks for each medical claim date for natalizumab and
12 weeks from each medical claim date for mitoxan-
trone [30,31]. As a part of the gap analysis, the number
of patients with evidence of the index DMD after a gap
of >60 days ("restarts”) were identified and the average
number of days to restart was measured. The length of
DMD therapy from the first until the last drug claim of
the index DMD was also measured. This measure
counted the number of days between the treatment
index date (i.e., the first drug claim for the index medi-
cation) and the last drug claim for the index medication
(including days of supply) during the study period,
regardless of gaps in therapy. The length of continuous
treatment with all DMD therapy was measured, both
with and without gaps of greater than 30 days. For each
patient’s drug regimen, the time from the first DMD
claim to the date of the last applicable DMD claim
(including days of supply) was measured, including any
DMD therapy that was received. Switching among
DMDs and discontinuation of all DMDs (i.e., no evi-
dence of any DMD for a 60-day period following the
end of the last observed prescription) was also analyzed.
Statistical analysis
Categorical variables were presented as counts and pro-
portions. Continuous variables were summarized by pro-
viding the number of observations, the mean, the
standard deviation, the median, and the range. Statistical
tests of significance for differences in these distributions
included Chi-square tests to evaluate the statistical sig-
nificance of differences for categorical variables, t-tests
and ANOVA for normally distributed continuous vari-
ables, while nonparametric Wilcoxon and Kruskal-
Wallis tests were used for continuous variables that are
not normally distributed. P-values of 0.050 or less were
considered statistically significant.
Multivariate regressions were conducted to control for
imbalances in observed baseline demographics and clini-
cal characteristics. Cox proportional hazards regressions
were used to assess characteristics associated with treat-
ment initiation with adjustment for time from diagnosis
to first treatment as well as to assess treatment persis-
tence, measured as the time to a 31 day gap in therapy,
among those treated. A logistic regression model was
also used to predict patient characteristics affecting the
initiation of treatment with DMDs. For each of the
three models, age and gender were included as covari-
ates and a backward elimination method was employed
to select among the many other characteristics, with the
variables remaining in each model each statistically sig-
nificant at a level of 5%. All statistical analyses were per-
formed using SAS version 9.2.
Results
Sample Attrition
Initially there were 67,869 Commercial and Medicare
patients with at least one inpatient or two non-diagnostic
outpatient claims at least 30 days apart with an MS diag-
nosis between January 1, 2001 and January 1, 2007. Of
these, 34,699 (51.1%) were excluded after applying twelve
months pre- and post-index continuous eligibility require-
ments, 306 (0.5%) were excluded who were under the age
of 18, and 21,803 patients (32.1%) were excluded who had
an MS diagnosis or DMD treatment during the pre-index
period, resulting in a final cohort of 11,061 patients.
Demographics
Population demographics are shown in Table 1. Females
comprised 74.2% of the study population. The average
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40.3% (n = 4,462) of patients treated with at least one of
the DMDs during the study period. The mean popula-
tion age was 50.3 ± 13.3 years, with DMD-treated
patients significantly younger (mean age 44.4 ± 10.6
years) than those without DMD treatment (mean age
54.3 ± 13.4 years, p < 0.001). The age distributions show
skewing of treatment to younger age groups, with 48.8%
of DMD-treated patients under the age of 44 compared
with 23.3% of untreated patients, and 2.2% of patients
over 65 with DMD treatment versus 20.7% of untreated
patients.
Clinical characteristics
Chronic pain conditions were the most frequently noted
comorbidities in the medical claims of this MS popula-
tion (Table 2), with over half of the cohort reporting
chronic skeletal pain (joint derangements, dorsopathies,
or polymyalgia rheumatica). With the exception of
fatigue, headache, depression, skin cancers, and sleep
disorders, all other comorbidities were noted in signifi-
cantly higher percentages of patients not treated with
DMDs. The Deyo-Charlson Comorbidity Index was cal-
culated for all patients, measured using pre-index
comorbidities, and was significantly lower for DMD-
treated patients, computed at 0.36 ± 0.86 for DMD-trea-
ted patients and 0.64 ± 1.24 for untreated patients, p <
0.001.
Treatment patterns
The most common index DMD used in treating these
incident patients was glatiramer (33.7% of treated inci-
dent patients) followed by interferon-beta-1a IM (32.1%)
and interferon-beta-1a SQ (20.5%) (Table 2). The start
of availability for interferon beta-1a SQ in the US in
February, 2002 is acknowledged as a factor possibly
underestimating its relative reported usage over the five-
year time span of this study. Similarly, it is noted that
Table 1 Patient Population Demographics
Demographic All patients DMD-treated Not DMD treated
N = 11,061 n = 4,462 n = 6,599
Gender
Male 25.8% 23.7% 27.2%
Female 74.2% 76.3% 72.8%
Age (in years, mean ± SD) 50.3 ± 13.3 44.5 ± 10.6 54.3 ± 13.4
18-34 11.5% 18.4% 6.8%
35-44 21.5% 30.4% 15.5%
45-54 31.2% 33.5% 29.7%
55-64 22.5% 15.6% 27.2%
65+ 13.2% 2.2% 20.7%
Insurance Type
Commercial 85.1% 96.9% 77.1%
Medicare 14.9% 3.1% 22.9%
Geographic Region
Northeast 12.9% 12.8% 13.0%
North Central 35.6% 32.0% 38.0%
South 30.4% 35.5% 27.0%
West 20.5% 19.2% 21.3%
Unknown 0.6% 0.5% 0.7%
Index year
2001 7.5% 8.0% 7.2%
2002 12.9% 13.0% 12.9%
2003 16.8% 17.7% 16.1%
2004 24.0% 22.1% 25.4%
2005 22.2% 22.5% 21.9%
2006* 16.6% 16.7% 16.5%
Length of follow-up (in months, mean ± SD) 35.7 ± 17.5 36.7 ± 17.6 35.1 ± 17.5
*Patients who indexed on January 1, 2007 are included in 2006 category
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2004, withdrawn in February 2005, and then re-
approved for relapsing MS in June 2006.
Other drugs used for acute MS exacerbations but
without established evidence of altering the course of
disease progression are also shown in Table 2. Gluco-
corticoids usage was highest in patients receiving DMDs
post-index (61.4%) compared with patients who were
not treated with DMDs post-index (40.0%). Usage of the
other agents was generally in 2% or fewer of patients.
No patients were found in this timeframe who had
received cladribine, daclizumab, or anti-lymphocyte glo-
bulin post-index.
Muscle relaxants, antidepressants, and anti-fatigue
agents were frequently prescribed post-index in this
population, also shown in Table 2, particularly among
DMD-treated patients whose percentage of patients with
drug use was significantly higher for all three of these
drug classes compared to untreated patients (p < 0.001).
Pre-index use of these medications was significantly
more prevalent in patients who did not receive DMD
treatment (muscle relaxants 16.1% DMD vs. 20.8% non-
Table 2 MS Comorbidities and Pharmacologic Treatments of Interest During the Post-Index Period
Comorbidity* DMD-treated
(n = 4,462)
Not DMD treated
(n = 6,599)
p-value
Joint derangement, dorsopathies, polymyalgia rheumatica 52.7% 57.1% <0.001
High blood pressure 30.5% 40.7% <0.001
High cholesterol 23.2% 28.6% <0.001
Cancers excluding skin cancer 22.2% 28.2% <0.001
Fatigue 25.1% 24.1% 0.231
Urinary tract infections 21.6% 25.9% <0.001
Headache 22.0% 21.9% 0.897
Neuropathic pain 19.6% 22.7% <0.001
Depression 21.0% 18.6% 0.002
Anxiety 18.3% 19.8% 0.049
Arthritis (RA & OA) 12.6% 21.4% <0.001
Skin cancers 13.8% 14.9% 0.107
Thyroid disease 12.2% 15.1% <0.001
Diabetes 8.8% 14.8% <0.001
Sleep disorders 11.5% 11.0% 0.469
Index DMD**
Glatiramer acetate 33.7%
Interferon beta-1a IM 32.1%
Interferon beta-1a SQ 20.5%
Interferon beta-1b 12.7%
Mitoxantrone 0.6%
Natalizumab 0.4%
Other medications used for treating MS exacerbations
Corticosteroids 61.4% 40.0% <0.001
Methotrexate 1.4% 2.0% 0.020
Azathioprine 1.3% 1.0% 0.165
Cyclosporine 1.2% 1.4% 0.336
Mycophenolate 1.1% 0.7% 0.027
IVIG 1.3% 0.6% <0.001
Cyclophosphamide 0.6% 0.5% 0.416
Muscle relaxants 37.6% 33.6% <0.001
Antidepressants 37.9% 30.4% <0.001
Anti-fatigue agents 32.7% 12.5% <0.001
*ICD-9-CM codes used for these conditions are available on request.
**First DMD on or after the patient’s index date.
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non-DMD, p = 0.018; anti-fatigue agents 3.5% DMD vs.
5.8% non-DMD, p < 0.001).
The mean time to therapy initiation was 5.3 ± 9.1
months following the index diagnosis (Table 3). Once
started on their index medication, more than three-
quarters (78.7%) of these patients stayed on their index
medication without switching to another DMD for the
duration of the follow-up period. Nearly three-quarters
of patients (71.0%) stayed on their index therapy an
average of 17.0 ± 15.9 months without gaps exceeding
30 days. Including the 21.3% of patients who switched
to another DMD after an average of 14.8 ± 12.9 months
on their index DMD, patients appeared to remain on all
DMD therapy without gaps exceeding 30 days for an
average of 18.8 ± 16.8 months. (Table 3)
There were 29.0% of patients with gaps in therapy
exceeding 30 days, and over 16% with gaps in excess of
60 days (restarting therapy), as shown in Table 3. Over-
all, 27.7% of patients discontinued DMD therapy alto-
gether after an average of 17.6 ± 14.6 months without
restarting any DMD therapy.
Factors with statistically significant associations with
the initiation of DMD therapy are shown in Table 4.
The hazard ratio denotes the odds that one group of
patients was treated with a DMD compared with a
reference group of patients, controlling for the influence
of other variables in the model and the length of follow-
up. Those variables associated with an increased
likelihood of initiating DMD therapy include patient age
(the lower the patient age, the higher the odds of being
treated), evidence of loss of coordination, and the occur-
rence of an NMRI or spinal tap prior to the index diag-
nosis. Factors associated with a decreased likelihood of
DMD initiation include higher degrees of comorbidity
(per the Deyo-Charlson Comorbidity Index showing a
13 percent decrease for each point rise in the index),
headache, sleep disorders, or the occurrence of pressure
ulcers prior to the index diagnosis, as well as the pre-
index use of azathioprine, anti-fatigue medications, or
muscle relaxants.
Factors with statistically significant associations with
the persistence on DMD therapy are shown in Table 5.
Those associated with an increased likelihood of persist-
ing on DMD therapy include female gender, age of 18
to 34, having an HMO insurance plan type, higher
degrees of comorbidity (Deyo-Charlson Comorbidity
Index), pre-index comorbidities of depression, headache,
or urinary tract infection, and pre-index use of antide-
pressants or muscle relaxants. Factors associated with a
decreased likelihood of DMD persistence include age
greater than 34 and pre-index neuropathic pain.
Discussion
This study investigated the demographics, clinical char-
acteristics, and treatment patterns for DMD therapy in
an adult managed care population of newly diagnosed
MS patients. Patients were followed for an average of
Table 3 Pharmacotherapy Treatment Persistence Patterns
Persistence Measure DMD-treated patients
(n = 4,462)
Persistence on DMD therapy Mean ± SD
Days from index diagnosis to 1
st DMD 158 ± 274
Days of continuous therapy for index DMDs (no gaps > 30 days) 511 ± 476
Days of continuous therapy for all DMDs (no gaps > 30 days) 565 ± 503
Days, first to last for index DMD (with gaps)* 683 ± 525
Days, first to last for all DMDs (with gaps)* 798 ± 540
Gap analysis for the index DMD % of patients
No gaps in index therapy > 30 days 71.0%
Gaps in index therapy of 31-60 days 20.6%
Gaps in index therapy > 60 days (restarts) 16.5%
Gaps of 61-90 days 8.4%
Gaps of 91-120 days 4.4%
Gaps > 120 days 8.3%
Mean days to restart (Mean ± SD) 159 ± 151
Switched from index DMD 21.3%
Mean days to switch (Mean ± SD) 445 ± 386
Discontinued all DMDs before end of follow-up† 27.7%
Mean days to discontinuation (Mean ± SD) 527 ± 437
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results indicate that 40.3% of incident patients received
treatment with at least one of the DMDs during the
post-index period. Population demographics were simi-
lar to a prior study done in a managed care population
[32]. Treated patients were primarily in the younger age
categories of 18-44 years of age, with DMD therapy
initiated an average of 5.3 ± 9.1 months after the index
diagnosis. Patients most likely to receive DMD therapy
were under the age of 45, had evidence of loss of coor-
dination, and had received NMRI or spinal tap pre-
index. Once treatment was initiated, 72.3% of DMD-
treated patients remained on therapy for the remainder
of their study period.
In the age categories of 18-34 and 35-44, most
patients received DMD treatment (64.7% and 57.0%
respectively), while most patients in the upper age cate-
gories did not receive DMD treatment (43% in ages 45-
54; 27.8% in ages 55-64; and, 6.6% in ages 65+). The
reasons for the increasing percentages of untreated
patients in the older groups are unknown, but disease
severity and disease stage are suspected contributors to
the decision not to opt for treatment. The use of retro-
spective claims data in the absence of the patient’sm e d i -
cal chart relies on the provider’sc o d i n go fa nM S
diagnosis, and contributes a very limited view of the
patient’s medical history. It is possible that the window of
12 months without MS claims prior to the first observed
MS claim may have resulted in misclassification, particu-
larly for patients with long-standing or advanced disease,
those in remission, or other patients no longer seeking
treatment. The low percentage of DMD treated patients
found in this analysis may be due in part to these limita-
tions and methodological issues. More rigorous confir-
mation of the accuracy of the diagnosis data were unable
to be performed due to patient de-identification require-
ments of the data sources. Differences in the frequency
of comorbidities may also be attributable to the differ-
ences in age between the DMD-treated and untreated
groups, as higher percentages of patients with arthropa-
thies, hypertension, hypercholesterolemia, cancers, UTIs,
thyroid disease and diabetes may be expected in the older
(untreated) population. In addition, a diagnosis was
required in only one claim for indication of a comorbidity
in this study, and so the percentage of patients with
comorbidities may be overestimated as some diagnosis
coding may have been either rule-outs or miscoding.
Adherence with DMDs can be complicated by many
factors [26,33], not the least of which are the concomi-
tant medications that patients may need to take for
relief of MS symptoms, such as muscle relaxants or
anti-fatigue medications, asw e l la sf o rc o m o r b i d i t i e s
that occur as a normal part of aging. The comorbidities
found post-index in this population are often medicated
chronically, such as the arthropathies, hypertension,
hyperlipidemia, depression, and neuropathic pain. Multi-
ple chronic medications can impose both a motivational
as well as financial burden on the patient.
This study found 71.0% of DMD-treated patients contin-
ued their index DMD treatment for 17.0 ± 15.9 months
without gaps exceeding 30 days, compared to an adher-
ence rate of 62% to 64% among patients taking insulin for
type 2 diabetes and 68% to 79% among patients taking
oral medications for heart failure [33]. In this study’s
cohort of newly diagnosed patients treated with DMDs,
there were 27.7% who discontinued DMD therapy after an
average of 17.6 ± 14.6 months. Although not directly com-
parable, Rio et al (2005) found in their cohort of 632
patients followed over 8 years (mean of 47.1 months) that
17% (107) stopped therapy with approximately half of
those stopping prior to 2 years [26], and O’Rourke (2005)
found a stopping rate for interferon-beta of 28%, as well as
an Italian study of RRMS that noted 41% of patients trea-
ted with interferon-beta had stopped after three years [28].
Table 4 Factors Associated with Initiation of DMD
Therapy
Parameter Hazard
Ratio
Pr >
ChiSq
Standard
Error
Gender (reference: male)
Female 0.998 0.949 0.037
Age group (reference: 18-34)
Age 35-44 0.845 <0.001 0.045
Age 45-54 0.641 <0.001 0.045
Age 55-64 0.424 <0.001 0.055
Age 65+ 0.107 <0.001 0.112
Pre-index comorbidities
Deyo-Charlson Comorbidity
Index
0.867 <0.001 0.020
Loss of coordination 1.537 <0.001 0.080
Headache 0.797 <0.001 0.042
Sleep disorders 0.781 0.002 0.079
Pressure ulcer 0.225 0.003 0.501
Pre-index pharmacotherapy
Anti-fatigue agent use 0.824 0.018 0.082
Azathioprine use 0.289 0.003 0.410
Corticosteroid use 1.081 0.031 0.036
Muscle relaxant use 0.823 <0.001 0.042
Pre-index testing
Electrocardiogram 0.883 0.001 0.038
Nuclear MRI 2.361 <0.001 0.035
Spinal tap 1.819 <0.001 0.043
* Table was created using a Cox Model adjusting for time to DMD initiation.
The dependent variable was days to DMD initiation. Shown in this table are
those factors of statistical significance (except gender). There were more
parameters modeled in each category and others eliminated using backward
selection.
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apy exceeding 30 days, and over 16% with gaps in excess
of 60 days. The reasons for discontinuance and non-
adherence gaps are not known. Costello et al (2008)
explored reasons for non-adherence to MS therapy and
found the key barriers to adherence to be problems with
injecting, perceived lack of efficacy, adverse events, and
treatment fatigue [33]. It has also been reported that
patients discontinuing treatment may also represent
higher disability or worsening response to the treatment
[26-28,33].
T h e r ei sag r o w i n gb o d yo fe v i d e n c et h a tp r o g r e s s i o n
of clinical disease occurs following cessation of DMD
therapy [24,25,34]. Drugs that can increase the conveni-
ence or tolerability to DMD treatment for MS patients
have the potential to increase the rate of early treatment
and overall adherence, offering benefit for those who
cannot tolerate or adhere to injectable medications
[35-44]. The advent of therapies with increased conveni-
ence, tolerability and efficacy is indeed encouraging for
advancing the treatment of MS.
Limitations
This study was subject to a number of limitations.
Using administrative claims data in the absence of the
patient medical charts, and limiting the look-back per-
iod to 12 months of pre-index claims history precluded
establishing each patient’sl o n gt e r mp r i o rd i s e a s eh i s -
tory. These factors also obscured a definitive MS diag-
nosis, the type of MS (e.g., relapsing-remitting, primary
progressive), identification of the initial date of an MS
diagnosis, therapy occurring prior to the start of the
study, disease severity, and the occurrence of relapse.
Claims analysis is limited in its ability to account for all
possible differences in patients and providers residing in
different states. In addition, misclassification errors are
possible when relying on diagnosis coding from admin-
istrative claims data and where the extent of undercod-
ing of diagnoses is unknown. In the absence of
diagnosis coding on pharmacy claims, it was assumed
that the drugs shown to be used for treating MS were
actually used as such. Further, the data sources did not
include information on patient assistance programs or
investigational drug treatment programs administered
outside of a health plan’s coverage or benefit plan, and
so only treatments submitted to a health plan for cover-
age were available for analysis. The databases represent
primarily employed or retired individuals, and thus may
not be generalizable to the entirety of the US MS
population.
Table 5 Factors Associated with Persistence on DMD Therapy
Parameter Hazard Ratio Pr > ChiSq Standard Error
Gender (reference: Male)
Female 1.117 0.035 0.052
Age group (reference: Age 18-34)
Age 35-44 0.701 <0.001 0.060
Age 45-54 0.618 <0.001 0.061
Age 55-64 0.672 <0.001 0.073
Age 65+ 0.847 0.274 0.152
Insurance plan type (reference: Comprehensive)
HMO 1.305 0.001 0.079
PPO 0.972 0.739 0.084
POS 1.096 0.170 0.067
POS with Capitation 1.002 0.984 0.109
Pre-index comorbidities
Deyo-Charlson Comorbidity Index 1.049 0.045 0.024
Depression 1.273 0.001 0.074
Headache 1.162 0.008 0.056
Neuropathic pain 0.844 0.003 0.058
Urinary tract infection 1.206 0.010 0.072
Pre-index pharmacotherapy
Antidepressant use 1.137 0.018 0.055
Muscle relaxant use 1.175 0.005 0.057
* This table was created using a Cox Model adjusting for time to DMD Therapy Gap of 31+ Days. The dependent variable was days to DMD therapy gap of 31+
days. Shown in this table are those factors of statistical significance. There were more parameters modeled in each category and others eliminated using
backward selection.
Margolis et al. BMC Neurology 2011, 11:122
http://www.biomedcentral.com/1471-2377/11/122
Page 8 of 10Conclusions
The decision to initiate DMD treatment, the choice of
therapy, and the extended deliberations to continue
treatment are complex. Individualized decisions made
by each patient with their provider consider many fac-
tors including disease severity, benefits of therapy, com-
parative effectiveness of available therapies, potential
side-effects, and the effects on a patient’sb u d g e ta n d
lifestyle. This study found that a large percentage of
newly-diagnosed MS patients remained untreated during
t h es t u d yp e r i o d ,t h a ta tl e a s taq u a r t e ro ft r e a t e d
patients stopped therapy during the time of this study,
and one-sixth of treated patients experienced treatment
gaps despite the risk of disease progression or a return
to pre-treatment disease activity. New pharmacologic
agents with increased convenience, tolerability and effi-
cacy have promise for improving the overall quality of
life for MS patients and their families.
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